Full-Life Technologies announced that it has signed an agreement to acquire Focus-X Therapeutics to expand its radiopharmaceuticals pipeline.
Focus-X’s proprietary radioligand therapy (RLT) delivers alpha or beta emitters to break down cancer cell DNA. The company has two core programs in its pipeline that are nearing clinical trials. One is a prostate-specific membrane antigen (PMSA)-targeted peptide to treat metastatic castration-resistant prostate cancer. The other is a neurotensin receptor type 1 (NTSR1)-targeted peptide to treat pancreatic cancer.
Focus-X will receive $245 million including upfront payments, potential development, regulatory and sales-based milestones and royalties for commercial sales.
Founded in 2021, Full-Life is a specialist in radiopharmaceuticals and has operations in Europe and China. Its discovery platform includes optimized single-domain antibodies, peptides and linkers to radionuclides.
The startup secured RMB 250 million ($35 million) in Series A funding rounds six months ago and completed a $10 million seed round financing in December 2021. The company’s pipeline mainly develops products targeting PSMA, NTSR1, Claudin 18.2 and GUCY2C/GCC.